{"totalCount":2,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT06236750","orgStudyIdInfo":{"id":"EFJP001"},"organization":{"fullName":"MiMedx Group, Inc.","class":"INDUSTRY"},"briefTitle":"Post-Marketing Surveillance of Dehydrated Human Amnion/Chorion Membrane (DHACM) in Non-Ischemic Chronic Wounds","officialTitle":"A Post-Marketing Surveillance to Observe the Safety and Efficacy of Dehydrated Human Amnion/Chorion Membrane (DHACM) Wound Graft in the Management of Non-Ischemic Chronic Wounds"},"statusModule":{"statusVerifiedDate":"2024-01","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-08-04","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2027-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-01-24","studyFirstSubmitQcDate":"2024-01-24","studyFirstPostDateStruct":{"date":"2024-02-01","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-01-24","lastUpdatePostDateStruct":{"date":"2024-02-01","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"MiMedx Group, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"CMIC Co, Ltd. Japan","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this survey is to observe the efficacy and safety of EPIFIX® dehydrated human amnion/chorion membrane (DHACM) for the treatment of intractable diabetic foot ulcers or venous leg ulcers.","detailedDescription":"The study will enroll 75 subjects diagnosed with intractable diabetic foot ulcers or venous leg ulcers at 5 plastic surgery sites in Japan. Subjects will be treated with weekly applications of EPIFIX for up to 12 weeks, followed by 6 months of follow-up."},"conditionsModule":{"conditions":["Diabetic Foot Ulcer","Venous Leg Ulcer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":75,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Patients with Non-Ischemic Chronic Wounds","type":"EXPERIMENTAL","description":"Patients with intractable diabetic foot ulcer or venous leg ulcer that have not decreased in surface area by at least 50% after 4 weeks of conventional therapies.","interventionNames":["Device: EPIFIX"]}],"interventions":[{"type":"DEVICE","name":"EPIFIX","description":"EPIFIX® is an allograft derived from dehydrated human amnion/chorion membrane. EPIFIX is a medical device in Japan (Generic name: Material using human amniotic membrane for promotion of tissue healing) for use on intractable ulcers that are non-responsive to existing therapies for the purpose of promoting wound healing.","armGroupLabels":["Patients with Non-Ischemic Chronic Wounds"],"otherNames":["DHACM"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Efficacy Endpoint: Healing of Ulcers at 4 Weeks, 8 Weeks, and 12 Weeks","description":"The percentage of patients to achieve wound closure at 4 weeks, 8 weeks, and 12 weeks after initial DHACM application, as a measure of healing rate.","timeFrame":"4 weeks, 8 weeks, and 12 weeks after initial application"},{"measure":"Safety Endpoint: Incidence of Adverse Events","description":"Incidence rate of adverse events in DHACM-treated patients during 12 weeks of treatment and 6 months of follow-up.","timeFrame":"9 months after initial application"}],"otherOutcomes":[{"measure":"Efficacy Endpoint: Reduction in Wound Size at 4 Weeks, 8 Weeks, and 12 Weeks","description":"Wound size will be measured at 4 weeks, 8 weeks, and 12 weeks after initial DHACM application, and the percent reduction of wound area will be calculated compared to baseline (week 0), as a measure of rate of wound closure.","timeFrame":"4 weeks, 8 weeks, and 12 weeks after initial application"},{"measure":"Efficacy Endpoint: Time to Complete Wound Healing during 12 Weeks of Application","description":"The amount of time after initial DHACM application to achieve complete epithelialization of the wound.","timeFrame":"12 weeks after initial application"},{"measure":"Efficacy Endpoint: Wound Recurrence for 6 months after Wound Closure","description":"The recurrence rate of healed ulcers will be monitored for 6 months after wound closure is achieved.","timeFrame":"6 months after wound closure"},{"measure":"Safety Endpoint: Incidence of Device Deficiencies","description":"Incidence rate of device deficiencies, severity, and details in DHACM-treated patients during 12 weeks of treatment and 6 months of follow-up.","timeFrame":"9 months after initial application"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPatients with intractable diabetic foot ulcers or venous leg ulcers that have not decreased in surface area by at least 50% after 4 weeks of conventional therapies, such as radical wound management (removal of necrotic tissue, infection control, wound cleansing, etc.), glycemic control for diabetic foot ulcers, compression therapy for venous stasis ulcers and moist therapy using wound dressing materials.\n\nExclusion Criteria:\n\n1. Areas of active infection or latent infection.\n2. Patients with disorders that would cause an intolerable risk of postoperative complications.\n3. Ulcers that cannot be sufficiently debrided.\n4. Ulcers that, after debridement, have blood flow disorders where wound bed necrosis progresses at an early stage.\n5. Wound surfaces with multiple ulcer surfaces and exposed bone, and no blood flow in the wound bed.\n6. Patients with hypersensitivity to the aminoglycoside antibiotics used during manufacturing.","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Chief Medical Officer","role":"CONTACT","phone":"770-651-9100","email":"CTInquiries@mimedx.com"}],"overallOfficials":[{"name":"David Mason, MD","affiliation":"MiMedx Group, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Kobe University Hospital","status":"RECRUITING","city":"Kobe","state":"Hyōgo","zip":"650-0017","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"Saitame Medical University Hospital","status":"RECRUITING","city":"Iruma-gun","state":"Saitama","zip":"350-0495","country":"Japan"},{"facility":"Juntendo University Hospital","status":"RECRUITING","city":"Bunkyō-Ku","state":"Tokyo","zip":"113-8431","country":"Japan"},{"facility":"Kyorin University Hospital","status":"RECRUITING","city":"Mitaka-shi","state":"Tokyo","zip":"181-8611","country":"Japan"},{"facility":"Tokyo Medical University Hospital","status":"RECRUITING","city":"Shinjuku-Ku","state":"Tokyo","zip":"160-0023","country":"Japan"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D017719","term":"Diabetic Foot"},{"id":"D014647","term":"Varicose Ulcer"}],"ancestors":[{"id":"D003925","term":"Diabetic Angiopathies"},{"id":"D014652","term":"Vascular Diseases"},{"id":"D002318","term":"Cardiovascular Diseases"},{"id":"D016523","term":"Foot Ulcer"},{"id":"D007871","term":"Leg Ulcer"},{"id":"D012883","term":"Skin Ulcer"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D048909","term":"Diabetes Complications"},{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D003929","term":"Diabetic Neuropathies"},{"id":"D014648","term":"Varicose Veins"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06600724","orgStudyIdInfo":{"id":"MIMEDX001"},"organization":{"fullName":"MiMedx Group, Inc.","class":"INDUSTRY"},"briefTitle":"Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs","officialTitle":"A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Evaluating PURION Processed Lyophilized Human Amnion/Chorion Membrane (ppLHACM) and Standard of Care Versus Standard of Care Alone in the Treatment of Nonhealing Diabetic Foot Ulcers","acronym":"CAMPAIGN"},"statusModule":{"statusVerifiedDate":"2024-09","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-08-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-08","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-08","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-09-16","studyFirstSubmitQcDate":"2024-09-16","studyFirstPostDateStruct":{"date":"2024-09-19","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-09-16","lastUpdatePostDateStruct":{"date":"2024-09-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"MiMedx Group, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"SerenaGroup, Inc.","class":"NETWORK"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This study will evaluate two human amnion/chorion membrane (ppLHACM) products and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs).","detailedDescription":"The CAMPAIGN trial is evaluating PURION Processed Lyophilized Human Amnion/Chorion Membrane (ppLHACM) and Standard of Care versus Standard of Care alone in the treatment of Nonhealing Diabetic Foot Ulcers. The study will evaluate two products, EPIEFFECT® and EPIXPRESS™, which are both ppLHACMs."},"conditionsModule":{"conditions":["Diabetic Foot Ulcer","Diabetic Foot","Foot Ulcer Due to Type 2 Diabetes Mellitus","Foot Ulcer, Diabetic","Foot Ulcer"],"keywords":["Ulcer","Foot Ulcer","Diabetic Foot Ulcer","Foot"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"CAMPAIGN uses a Prospective Modified Platform Multicenter Randomized Controlled Clinical Trial design.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":170,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Standard of Care","type":"ACTIVE_COMPARATOR","description":"Standard of care will be cleaning, debridement, ulcer moisture balance, and offloading.","interventionNames":["Other: Standard of Care"]},{"label":"EPIEFFECT","type":"EXPERIMENTAL","description":"EPIEFFECT® is a PURION processed lyophilized human placental tissue allograft that includes the amnion layer, intermediate layer, and chorion layer of the amniotic membrane. The product is intended for use as a barrier to provide a protective environment in acute and chronic wounds.","interventionNames":["Other: EPIEFFECT"]},{"label":"EPIXPRESS","type":"EXPERIMENTAL","description":"EPIXPRESS™ is a PURION processed lyophilized human placental tissue allograft that includes the amnion layer, intermediate layer, and chorion layer of the amniotic membrane. The product is intended for use as a barrier to provide a protective environment in acute and chronic wounds. EPIXPRESS is fenestrated to help facilitate fluid movement and can be used on wounds that produce copious amounts of exudate.","interventionNames":["Other: EPIXPRESS"]}],"interventions":[{"type":"OTHER","name":"Standard of Care","description":"Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.","armGroupLabels":["Standard of Care"]},{"type":"OTHER","name":"EPIEFFECT","description":"Participants will receive weekly applications of EPIEFFECT and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first","armGroupLabels":["EPIEFFECT"]},{"type":"OTHER","name":"EPIXPRESS","description":"Participants will receive weekly applications of EPIXPRESS and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first","armGroupLabels":["EPIXPRESS"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of target ulcers achieving wound closure","description":"The percentage of target ulcers achieving complete wound closure in 12 weeks.","timeFrame":"1 - 12 weeks"}],"secondaryOutcomes":[{"measure":"Percent of wound closure area","description":"Percentage wound area reduction from treatment visit (TV)-1 to TV-13 measured weekly with digital photographic planimetry and physical examination","timeFrame":"1 - 12 weeks"},{"measure":"Adverse Events","description":"Number of adverse events will be evaluated weekly","timeFrame":"1 - 12 weeks"},{"measure":"Change in Pain in Target Ulcer","description":"Change in pain in the target ulcer assessed using the Pain, Enjoyment of Life and General Activity (PEG) scale","timeFrame":"1 - 12 weeks"},{"measure":"Change in Quality of Life","description":"Change in quality-of-life using the Wound Quality of Life (wQOL) questionnaire","timeFrame":"1 - 12 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. At least 18 years of age or older.\n2. Diagnosis of type 1 or 2 Diabetes mellitus.\n3. At randomization subjects must have a target ulcer with a minimum surface area of 0.7 cm\\^2 and a maximum surface area of 5.0 cm\\^2 measured post debridement.\n4. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care, prior to the initial screening visit.\n5. The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus.\n6. The target ulcer must be Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the medial aspect of the malleolus. The ulcer may not include exposed tendon or bone.\n7. The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:\n\n   1. Ankle-Brachial Index (ABI) between 0.7 and ≤ 1.3;\n   2. Toe-Brachial Index (TBI) ≥ 0.6;\n   3. Transcutaneous Oxygen Measurement (TCOM) ≥ 40 mmHg;\n   4. Pulse Volume Resistance (PVR): biphasic.\n8. If the potential subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.\n9. Target ulcers located on the plantar aspect of the foot must be offloaded for at least 14 days prior to enrollment.\n10. The potential subject must consent to using the prescribed offloading method for the duration of the study.\n11. The potential subject must agree to attend the weekly study visits required by the protocol.\n12. The potential subject must be willing and able to participate in the informed consent process.\n\nExclusion Criteria:\n\n1. The potential subject is known to have a life expectancy of \\< 6 months.\n2. The potential subject's target ulcer is not secondary to diabetes.\n3. The target ulcer is infected or there is cellulitis in the surrounding skin.\n4. The target ulcer exposes tendon or bone.\n5. There is evidence of osteomyelitis complicating the target ulcer.\n6. There is an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.\n7. The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).\n8. The potential subject is taking hydroxyurea.\n9. The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.\n10. The potential subject with a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer.\n11. The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.\n12. The surface area of the target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit (\"historical\" run-in period). MolecuLight Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).\n13. The surface area measurement of the Target ulcer decreases by 20% or more during the 2-week screening phase: the 2 weeks from the initial screening visit (S1) to the TV-1 visit during which time the potential subject received SOC.\n14. The potential subject has an acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer.\n15. Women who are pregnant or considering becoming pregnant within the next 6 months are excluded.\n16. The potential subject has end stage renal disease requiring dialysis.\n17. Participation in a clinical trial involving treatment with an investigational product within the previous 30 days.\n18. A potential subject who, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.\n19. The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.\n20. The potential subject has a malnutrition indicator score \\<17 as measured on the Mini Nutritional Assessment.\n21. A subject has a wound with active or latent infection is excluded.\n22. A subject with a disorder that would create unacceptable risk of post-operative complications is excluded.\n23. A subject with a known sensitivity to aminoglycoside antibiotics is excluded.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Brittany Bonafide","role":"CONTACT","phone":"888-960-1343","email":"bbonafide@serenagroups.com"},{"name":"Thomas Serena, MD","role":"CONTACT","email":"tserena@serenagroups.com"}],"overallOfficials":[{"name":"Thomas Serena, MD","affiliation":"SerenaGroup, Inc.","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Dennis McMahon, MD","affiliation":"MiMedx Group, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"SerenaGroup - Monroeville","status":"RECRUITING","city":"Monroeville","state":"Pennsylvania","zip":"15146","country":"United States","contacts":[{"name":"Laura Serena","role":"CONTACT","phone":"412-212-0123","email":"LSerena@serenagroups.com"}],"geoPoint":{"lat":40.42118,"lon":-79.7881}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D017719","term":"Diabetic Foot"},{"id":"D016523","term":"Foot Ulcer"},{"id":"D014456","term":"Ulcer"}],"ancestors":[{"id":"D003925","term":"Diabetic Angiopathies"},{"id":"D014652","term":"Vascular Diseases"},{"id":"D002318","term":"Cardiovascular Diseases"},{"id":"D007871","term":"Leg Ulcer"},{"id":"D012883","term":"Skin Ulcer"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D048909","term":"Diabetes Complications"},{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D003929","term":"Diabetic Neuropathies"},{"id":"D005534","term":"Foot Diseases"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"D059039","term":"Standard of Care"}],"ancestors":[{"id":"D019984","term":"Quality Indicators, Health Care"},{"id":"D011787","term":"Quality of Health Care"},{"id":"D006298","term":"Health Services Administration"},{"id":"D017530","term":"Health Care Quality, Access, and Evaluation"}]}},"hasResults":false}
]}